Fidelity Top Stories
CanSino Biologics successfully completes second phase clinical trial
The global race to develop a vaccine against the novel coronavirus intensified at the start of the week as the Chinese company working on that country's front-runner announced the successful completion of a second-phase trial.
Synairgen treatment reduces risk of 'severe' Covid-19 by 79%
Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.
GSK takes 10% stake in CureVac for £130m in collaboration deal
GlaxoSmithKline said it would invest £130m to take a 10% stake in Germany's CureVac and collaborate to develop up to five mRNA-based vaccines and antibodies to fight infectious diseases.
UK expected to suspend Hong Kong extradition treaty
UK foreign secretary Dominic Raab is set to announce the result of a review on Monday over a possible suspension of the extradition treaty with Hong Kong in protest over the new national security law imposed on the special administrative area by Beijing.
Amigo swings to loss after huge rise in customer complaints
Lender Amigo swung to a full year loss after a massive increase in customer complaints.
Some EU leaders see path to deal on Reconstruction Fund, talks to resume later
Some European Union leaders believe a deal on the bloc's Reconstruction Fund was now in sight after the four countries which had been holding out for greater conditionality signalled their agreement with the proposed split between grants and low-interest loans.
UK's biggest firms expect long haul to recovery
Finance chiefs in the UK remained divided on the expected speed of the recovery in their business but were a bit less downbeat, the results of the a closely-followed survey showed.
UBS and Morgan Stanley expected to lead Vodafone Tower IPO
Swiss investment bank UBS and its US rival Morgan Stanley are the front-runners to organise the listing of Vodafone's European towers unit.